Cargando…

Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial

OBJECTIVES: The Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout (CARES) trial suggested a higher risk of cardiovascular (CV) death from febuxostat than from allopurinol. However, a significant number of patients died after discontinuation of febuxostat or allopurinol. We inv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghang, Byeong-zu, Lee, Ji Sung, Choi, Jihye, Kim, Jinseok, Yoo, Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Crystal Arthropathies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9226988/ https://www.ncbi.nlm.nih.gov/pubmed/35732345 http://dx.doi.org/10.1136/rmdopen-2021-001944

Ejemplares similares

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study
por: Fleischmann, Roy, et al.
Publicado: (2018)

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study
por: Fleischmann, Roy, et al.
Publicado: (2018)

Development of a patient decision aid for the initiation of urate-lowering therapy in gout patients
por: te Kampe, Ritch, et al.
Publicado: (2022)

Safety of colchicine and NSAID prophylaxis when initiating urate-lowering therapy for gout: propensity score-matched cohort studies in the UK Clinical Practice Research Datalink
por: Roddy, Edward, et al.
Publicado: (2023)

Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality
por: Pérez Ruiz, Fernando, et al.
Publicado: (2019)

Diagnostic value of ultrasound in calcium pyrophosphate deposition disease: a systematic review and meta-analysis
por: Gamon, Etienne, et al.
Publicado: (2015)

Relationship between tissue stress during gait in healthy volunteers and patterns of urate deposition and bone erosion in gout: a biomechanical computational modelling study
por: Dalbeth, Nicola, et al.
Publicado: (2015)

Tophus resolution with pegloticase: a prospective dual-energy CT study
por: Araujo, Elizabeth G, et al.
Publicado: (2015)

Prevalence and incidence of gout in southern Sweden from the socioeconomic perspective
por: Kapetanovic, Meliha C, et al.
Publicado: (2016)

Systematic review and quality analysis of emerging diagnostic measures for calcium pyrophosphate crystal deposition disease
por: Wu, Y, et al.
Publicado: (2016)

Identification of monosodium urate crystal deposits in patients with asymptomatic hyperuricemia using dual-energy CT
por: Wang, Penny, et al.
Publicado: (2018)

Multiple common and rare variants of ABCG2 cause gout
por: Higashino, Toshihide, et al.
Publicado: (2017)

Gout and the risk of incident atrial fibrillation in older adults: a study of US Medicare data
por: Singh, Jasvinder A, et al.
Publicado: (2018)

Influence of genetic variants on renal uric acid handling in response to frusemide: an acute intervention study
por: Dalbeth, Nicola, et al.
Publicado: (2017)

Occupational exposure to inorganic dust and risk of gout: a population-based study
por: Sigurdardottir, Valgerdur, et al.
Publicado: (2020)

Subtype-specific gout susceptibility loci and enrichment of selection pressure on ABCG2 and ALDH2 identified by subtype genome-wide meta-analyses of clinically defined gout patients
por: Nakayama, Akiyoshi, et al.
Publicado: (2020)

Genome-wide association study revealed novel loci which aggravate asymptomatic hyperuricaemia into gout
por: Kawamura, Yusuke, et al.
Publicado: (2019)

Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care
por: Roddy, Edward, et al.
Publicado: (2020)

12-month results from the real-life observational treat-to-target and tight-control therapy NOR-Gout study: achievements of the urate target levels and predictors of obtaining this target
por: Uhlig, Till, et al.
Publicado: (2021)

Serum uric acid control for prevention of gout flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance claims and medical check-up data in Japan
por: Koto, Ruriko, et al.
Publicado: (2021)

Association between serum urate level and carotid atherosclerosis: an insight from a post hoc analysis of the PRIZE randomised clinical trial
por: Tanaka, Atsushi, et al.
Publicado: (2022)

Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) common language definition of gout
por: Murdoch, Rachel, et al.
Publicado: (2021)

High prevalence of chondrocalcinosis and frequent comorbidity with calcium pyrophosphate deposition disease in patients with seronegative rheumatoid arthritis
por: Krekeler, Martin, et al.
Publicado: (2022)

Urate crystal deposition is associated with inflammatory markers and carotid artery pathology in patients with intercritical gout: results from the NOR-Gout study
por: Hammer, Hilde Berner, et al.
Publicado: (2022)

Case report: crowned dens syndrome in a patient with seronegative rheumatoid arthritis
por: Ferraccioli, Gianfranco, et al.
Publicado: (2023)

Filling gaps in female gout: a cross-sectional study of comorbidities in 192 037 hospitalised patients
por: Rodríguez-Sosa, Enrique, et al.
Publicado: (2023)

Dynamic assessment of the double contour sign by ultrasonography helps to distinguish between gout and calcium pyrophosphate deposition disease
por: Cipolletta, Edoardo, et al.
Publicado: (2023)

Factors influencing the kinetics of MSU crystal depletion measured with dual-energy CT in patients with gout
por: Laurent, Victor, et al.
Publicado: (2023)

Spontaneous resolution of acute gout: mechanisms and therapeutic targets
por: Shi, Meiling, et al.
Publicado: (2023)

Lifestyle factors predict gout outcomes: Results from the NOR-Gout longitudinal 2-year treat-to-target study
por: Uhlig, Till, et al.
Publicado: (2023)

Updated Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol
por: Pawar, Ajinkya, et al.
Publicado: (2021)

Diabetes and gout: efficacy and safety of febuxostat and allopurinol
por: Becker, M A, et al.
Publicado: (2013)

Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System
por: Bai, Yang, et al.
Publicado: (2023)

Entities inside one another ‐ a matryoshka doll in biology?
por: Woyke, Tanja, et al.
Publicado: (2018)

A retrospective observational study of the appropriate starting dose of febuxostat in patients with gout
por: Lee, Joondon, et al.
Publicado: (2023)

Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis
por: Guan, Xudong, et al.
Publicado: (2022)

Stories of the future: manipulating RNA and Intra/Interkingdom communication
por: Arraiano, Cecilia Maria
Publicado: (2018)

Switching from allopurinol to febuxostat: efficacy and tolerability in hemodialysis patients
por: Mitsuboshi, Satoru, et al.
Publicado: (2015)

Evaluation of effect of allopurinol and febuxostat in behavioral model of depression in mice
por: Karve, Ashwini V., et al.
Publicado: (2013)

The potential renoprotection of xanthine oxidase inhibitors: Febuxostat versus allopurinol
por: Ryu, Dong-Ryeol
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_1t695k8d9dkfksuhgu9ieodhkv